IRIS Institutional Research Information System - OPENBS Open Archive UniBS

QUIROS ROLDAN, Maria Eugenia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.243
AS - Asia 9.866
EU - Europa 7.520
SA - Sud America 2.113
AF - Africa 186
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 14
Totale 38.975
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.936
SG - Singapore 3.424
CN - Cina 3.131
UA - Ucraina 1.766
BR - Brasile 1.753
HK - Hong Kong 1.397
DE - Germania 1.372
IT - Italia 1.025
PL - Polonia 664
VN - Vietnam 610
FI - Finlandia 588
GB - Regno Unito 560
RU - Federazione Russa 460
TR - Turchia 390
IE - Irlanda 369
IN - India 322
FR - Francia 197
CA - Canada 146
AR - Argentina 127
BD - Bangladesh 115
SE - Svezia 109
MX - Messico 100
NL - Olanda 83
AT - Austria 73
ZA - Sudafrica 70
EC - Ecuador 69
JP - Giappone 69
ID - Indonesia 67
IQ - Iraq 65
ES - Italia 55
CZ - Repubblica Ceca 41
PK - Pakistan 36
VE - Venezuela 34
BE - Belgio 32
AU - Australia 31
LT - Lituania 31
SA - Arabia Saudita 31
UZ - Uzbekistan 31
CO - Colombia 29
IR - Iran 29
PY - Paraguay 26
CL - Cile 23
MA - Marocco 21
AE - Emirati Arabi Uniti 20
EG - Egitto 20
KE - Kenya 19
PE - Perù 19
UY - Uruguay 19
IL - Israele 18
JO - Giordania 16
JM - Giamaica 15
EU - Europa 14
AZ - Azerbaigian 13
BO - Bolivia 12
RO - Romania 12
DZ - Algeria 11
TN - Tunisia 11
CH - Svizzera 10
MU - Mauritius 10
PA - Panama 10
HN - Honduras 9
CR - Costa Rica 8
KZ - Kazakistan 8
AL - Albania 7
AM - Armenia 7
ET - Etiopia 7
HU - Ungheria 7
KR - Corea 7
NP - Nepal 7
PH - Filippine 7
PT - Portogallo 7
BY - Bielorussia 6
LV - Lettonia 6
BB - Barbados 5
KG - Kirghizistan 5
MK - Macedonia 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
EE - Estonia 4
GE - Georgia 4
MN - Mongolia 4
MY - Malesia 4
OM - Oman 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
UG - Uganda 4
CI - Costa d'Avorio 3
DK - Danimarca 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
NO - Norvegia 3
SI - Slovenia 3
TH - Thailandia 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CM - Camerun 2
GA - Gabon 2
Totale 38.943
Salva come PNG Salva come JPEG
Città #
Fairfield 2.267
Woodbridge 1.906
Ashburn 1.691
Singapore 1.682
Hong Kong 1.396
Jacksonville 1.335
Houston 1.265
Seattle 952
Cambridge 916
Wilmington 879
Ann Arbor 839
Chandler 730
Warsaw 656
Princeton 634
Beijing 606
Nanjing 467
New York 456
Los Angeles 388
Dublin 362
Istanbul 314
Helsinki 309
The Dalles 262
Munich 228
Ho Chi Minh City 214
Des Moines 193
Nanchang 190
Dearborn 183
Moscow 181
Brescia 174
São Paulo 173
Buffalo 172
Dallas 154
San Diego 137
Changsha 132
Milan 132
Shenyang 131
Shanghai 130
Hebei 124
Redondo Beach 121
Chicago 116
San Francisco 115
Jinan 113
Hanoi 108
Lancaster 99
London 93
Tianjin 91
Nuremberg 75
Turku 66
Jiaxing 65
Tokyo 64
Hangzhou 61
Kunming 59
Santa Clara 56
Frankfurt am Main 51
Rio de Janeiro 51
Toronto 51
Montreal 47
Brooklyn 45
Guangzhou 45
Zhengzhou 42
Belo Horizonte 41
Chennai 39
Denver 39
Verona 39
Ningbo 38
Atlanta 37
Johannesburg 37
Mexico City 37
Porto Alegre 37
Phoenix 35
Stockholm 35
Jakarta 34
Brasília 33
Haiphong 33
Orem 33
Poplar 33
Boston 32
Charlotte 32
Düsseldorf 32
Washington 32
Boardman 31
Brno 31
Brussels 30
Curitiba 30
Dong Ket 30
Kocaeli 29
Romola 29
Taizhou 29
Tashkent 29
Manchester 27
Vienna 27
Lanzhou 26
Leawood 26
Campinas 25
Salt Lake City 25
Ardabil 24
Da Nang 24
Quito 24
San Mateo 24
Rome 23
Totale 25.845
Salva come PNG Salva come JPEG
Nome #
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 396
The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia 280
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study 252
Modulation of Regulatory T-cell Subsets in Very Long-term Treated Aviremic HIV(+) Patients and Untreated Viremic patients 249
Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA 234
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz 220
Effectiveness of routine lumbar puncture in patients with HIV-associated Dementia (HAD) receiving suppressive antiretroviral treatment 215
Burden of Non-AIDS-Defining and Non-Virus-Related Cancers Among HIV-Infected Patients in the Combined Antiretroviral Therapy Era. 210
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 206
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 201
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 193
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study 191
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 190
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 189
Prevalence of integrase strand transfer inhibitors (InSTIs) resistance mutations in InSTIs-naive and -experienced HIV-1 infected patients: a single Center experience 185
Hepatitis C infection influence on immune recovery in HIV-positive patients on successful HAART: The role of genotype 3 185
Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules. 179
Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy 179
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 179
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study 175
Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. 170
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 168
Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study 165
HIV-associated asymmetric lipodystrophy syndrome 164
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 161
Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012 161
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 160
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 160
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 159
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 158
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 157
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 156
Evidence for antigenic selection of large granular lymphocytes in a patient with Wiskott-Aldrich syndrome 155
Breast cancer among human immunodeficiency virus (HIV)-infected patients: the experience in Brescia, Northern Italy. 154
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 154
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 153
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 153
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 152
An enzyme-linked (alkaline phosphatase) oligonucleotide probe for the detection of serum hepatitis B virus DNA. 151
Lung cancer in HIV-infected patients: the experience in Brescia from 1999 to 2009 151
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 150
A population-based database to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009 149
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 147
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 147
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 147
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 147
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 146
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 146
Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy 146
Mapping the human genetic architecture of COVID-19 145
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 145
Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort 145
Prevalence of non-B HIV-1 subtypes in North Italy and analysis of transmission clusters based on sequence data analysis 145
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 144
Peripheral loss of regulatory T cells and polyautoimmunity in an HIV-infected patient 144
Disseminated Histoplasmosis as AIDS-presentation. Case Report and Comprehensive Review of Current Literature 144
Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults 144
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 143
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 143
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 143
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 143
The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population 143
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 142
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 141
A COPD case-finding program in a large cohort of HIV-infected persons 140
Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life 140
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 139
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. 138
An outbreak of Serratia marcescens bloodstream infections associated with misuse of drug vials in a surgical ward 137
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients 137
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 136
The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients 136
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 136
Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir 135
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort 135
Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy,1999-2009 134
Immune complex p24 antigen: a new prognostic marker in human immunodeficiency virus infection 133
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 132
Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort 131
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 130
Compassionate Use of Remdesivir for Patients with Severe Covid-19 130
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study 130
Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy 129
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). 128
Different TCRBV genes generate biased patterns of V-D-J diversity in human T cells 128
A first update on mapping the human genetic architecture of COVID-19 127
Serum hepatitis B virus DNA detection with S- and C-region-directed probes 127
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study 127
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. 126
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 126
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 126
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir 126
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 126
Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy 125
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial 125
Polymorphic immune restoration syndrome after effective HAART 125
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 125
Elderly women with human immunodeficiency virus infection: is there an effect of the virus on neuropsychological prolife? 125
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 125
Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy 125
Totale 15.649
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.314
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 203.314
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.946 0 0 0 0 0 529 171 523 548 479 504 192
2021/20222.514 172 390 75 149 37 133 155 183 127 298 208 587
2022/20232.341 354 69 46 152 185 635 10 227 381 38 112 132
2023/20242.499 130 72 224 196 107 423 78 108 647 30 70 414
2024/20256.810 81 45 74 788 748 643 687 229 782 662 1.254 817
2025/20268.303 1.309 1.736 1.022 1.996 1.660 580 0 0 0 0 0 0
Totale 39.581